TEL AVIV, Israel, June 01, 2016 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to treat patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome (Fragile X), today announced corporate presentations at the upcoming Jefferies 2016 Healthcare Conference and the ROTH 3rd Annual Healthcare Day.
|Jefferies 2016 Healthcare Conference|
|Date:||Wednesday, June 8|
|Time:||8:00am Eastern Daylight Time|
|Location:||Grand Hyatt Hotel, New York City|
|ROTH 3rd Annual Healthcare Day|
|Date:||Wednesday, June 22|
|Location:||The Dorchester Hotel, London UK|
About Alcobra Ltd.
Alcobra Ltd. is an emerging pharmaceutical company primarily focused on the development and commercialization of MDX, a proprietary drug candidate, to treat cognitive disorders including ADHD and Fragile X. For more information please visit the Company's website, www.alcobra-pharma.com, the content of which is not incorporated herein by reference.
U.S. Investor Contacts LifeSci Advisors, LLC Michael Rice 646-597-6979 email@example.com Media Inquiries Sam Brown, Inc. Mike Beyer 773-463-4211 firstname.lastname@example.org Israel Investor Contact: Alcobra Investor Relations Debbie Kaye +972-72 2204661 email@example.com